Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic ...

The issues are complex, with no single causative factor. Yet central to these changes is the role of volition – human agency. Women everywhere have made and are making their own decisions about ...

"The doctor and his lawyers came up with the idea that we couldn’t proceed because, under Minnesota workers’ compensation law ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Quoin CEO Michael Myers said, "2024 was without a doubt the most significant ... our product candidate for Netherton Syndrome ...

Quoin CEO Dr. Michael Myers, said, “While cautioning upfront ... of QRX003 as a chronic whole-body treatment of Netherton Syndrome. After just two weeks of treatment, a transformational life ...

Quoin Pharmaceuticals (QNRX) announced recent corporate accomplishments and provided an update on its fourth quarter and full-year 2024 ...

Treatment Market is expected to grow steadily, driven by the rising prevalence of hormonal disorders, infertility, and ...

Letters to the editor should be 250 words or less. Include your name and city or community of residence. Guest opinions ...

Quoin CEO Dr. Michael Myers, said, “While cautioning upfront that this data ... of the potential efficacy of QRX003 as a chronic whole-body treatment of Netherton Syndrome. After just two weeks of ...

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...